CAS
ATHE

Coppell Advisory Solutions’s Alterity Therapeutics ATHE Stock Holding History

Coppell Advisory Solutions’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5
Closed -$18 – 437
2024
Q4 		$18 Hold
5
– – ﹤0.01% 1960
2024
Q3 		$7 Hold
5
– – ﹤0.01% 1869
2024
Q2 		$9 Buy
+5
New +$10 ﹤0.01% 1785
2023
Q4 		$12 Sell
5
-144
-97% -$356 ﹤0.01% 1707
2023
Q3 		$52 Buy
149
+141
+1,763% +$391 ﹤0.01% 1167
2023
Q2 		$22 Buy
+8
New +$23 ﹤0.01% 1418
2023
Q1 		– Sell
-15
Closed -$52 – 259
2022
Q4 		$52 Buy
+15
New +$57 ﹤0.01% 1167

Other funds holding ATHE

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
TLCM
Twin Lakes Capital Management Redwood Shores, California $220M AUM 31.75% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Coppell Advisory Solutions's ATHE Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Alterity Therapeutics (ATHE) in Q1 2025, closing a stake of 5 shares — an estimated $18 sold.

Coppell Advisory Solutions first reported a position in ATHE in Q4 2022 and held it in 7 quarters. The position peaked at $52 in Q3 2023. 12 funds tracked by Wall St. Rank hold ATHE as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Alterity Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 5 Alterity Therapeutics shares in Q1 2025, an estimated $18.
  • Coppell Advisory Solutions first reported a position in Alterity Therapeutics in Q4 2022 and held it in 7 quarters.
  • Coppell Advisory Solutions's Alterity Therapeutics position peaked at $52 in Q3 2023.
  • 12 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.